Author
Listed:
- Louis S. Matza
(Evidera)
- Nan Li
(Janssen Pharmaceutical K.K)
- Katie D. Stewart
(Evidera)
- Mahmoud Hashim
(Janssen Global Services, LLC)
- Tom Denee
(Middle East and Africa)
- Feng Pan
(Janssen Global Services, LLC)
- Qiaoyi Zhang
(Janssen Global Services, LLC)
- Jennifer Lee
(Middle East and Africa)
- Michel Michaelides
(UCL Institute of Ophthalmology and Moorfields Eye Hospital)
- Hendrik P. N. Scholl
(Medical University of Vienna
Pallas Kliniken AG, Pallas Klinik Zürich
European Vision Institute)
Abstract
Background X-linked retinitis pigmentosa (XLRP) is a rare, inherited retinal disease characterized by impairment in visual field and visual acuity with continuous progression leading to blindness. Gene therapies for XLRP are under investigation, and health state utilities are needed for use in cost-utility analyses examining the value of these treatments. Objective This study aimed to estimate utilities associated with XLRP severity. Methods Eleven health state vignettes depicting combinations of impairment in visual field and visual acuity associated with XLRP were developed based on literature review and input from clinicians, patients, and a caregiver. Vignettes included text describing visual acuity impairment, visual field impairment, night blindness, impact on quality of life, and two images representing the combination of visual field and visual acuity impairment for each health state. Health states were valued in time trade-off interviews with general population respondents in the UK. Results A total of 245 participants completed interviews (51.0% female; mean age = 41.4 years; Newcastle, n = 80; London, n = 85; Edinburgh, n = 80). In a ranking task, participants preferred health states with less severe visual impairment, and this preference was reflected in the utilities. Mean (standard deviation) utilities ranged from 0.900 (0.121) for the health state with no visual acuity impairment and mild visual field impairment to 0.271 (0.478) for the health state describing blindness. Conclusion Results highlight the substantial impact of visual impairment on health state preference and quality of life. The health state utilities estimated in this study may be appropriate for use in cost-effectiveness models evaluating treatments for XLRP. JEL CLASSIFICATION CODES I1; I12; I19
Suggested Citation
Louis S. Matza & Nan Li & Katie D. Stewart & Mahmoud Hashim & Tom Denee & Feng Pan & Qiaoyi Zhang & Jennifer Lee & Michel Michaelides & Hendrik P. N. Scholl, 2025.
"Health state utilities associated with X-linked retinitis pigmentosa (XLRP),"
The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 26(7), pages 1263-1273, September.
Handle:
RePEc:spr:eujhec:v:26:y:2025:i:7:d:10.1007_s10198-025-01761-y
DOI: 10.1007/s10198-025-01761-y
Download full text from publisher
As the access to this document is restricted, you may want to
for a different version of it.
More about this item
Keywords
;
;
;
;
;
;
JEL classification:
- I1 - Health, Education, and Welfare - - Health
- I12 - Health, Education, and Welfare - - Health - - - Health Behavior
- I19 - Health, Education, and Welfare - - Health - - - Other
Statistics
Access and download statistics
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:26:y:2025:i:7:d:10.1007_s10198-025-01761-y. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.